Molecular Characterization and Therapeutic Management of Prostate Cancer
The clinical management of metastatic prostate cancer is improving at a rapid pace, increasingly influenced by the advancement in molecular characterization of this disease. In particular, the identification of driver mutations and delineation of the molecular signatures of have resulted in significant improvements in the array of treatment options for this disease and improved individualization of prognosis. There are still uncertainties regarding the management of early prostate cancer. This meeting will provide an opportunity to hear from leading national and international experts on how recently published data may change practice, some of which will have immediate clinical applications. Furthermore, each session will have multiple segments on novel emerging treatment paradigms likely to transform the care of metastatic prostate cancer in the near future.
This virtual conference is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:
- Advances in the identification of molecular driver mutations that impact prognosis for patients with Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Use of molecular treatments in metastatic prostate cancer
- Discussion of immediate versus delayed systemic therapy for patients with biochemical (PSA) failure after definitive, local treatment
- Role of molecular imaging (PET based imaging) to clarify staging
Registration is free for healthcare providers who are NOT employees of ACCME defined ineligible companies.
If you are a healthcare provider involved in patient care and are not an employee of an ineligible company, please proceed to registration and select "non-industry learner" and your fee will reset to $0.00.
An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients. If you are an employee of an ineligible company, please select "industry representative" and pay the industry registration fee when registering for this conference.
Any unpaid participation by industry professionals will be billed an additional $150 for a total of $356 per person.
Upon successful completion of this educational activity, participants will be able to:
- Explain the nuances of the data regarding optimal timing of initiation of androgen deprivation therapy (ADT) for patients with biochemical failure
- Review recent data on the use of genomic testing to define the prognosis of patients with mCSPC
- Summarize genomic testing to select treatment for metastatic castration-resistant prostate cancer
- Discuss the optimal use of molecular imaging tests
All times are listed in Pacific Standard Time (PST)
May 8th, 2021
7:15 AM PST: Zoom Link Opens
7:15 AM to 7:30 AM PST: Attendance/Exhibit
7:30 AM to 7:45 AM PST: Introduction and discussion about the Binaytara Foundation – Dr. Binay Shah
7:45 AM to 8:00 AM PST: Welcome/Pre-test questions - Dr. Benjamin L. Maughan
8:00 AM to 8:25 AM PST: The role of molecular imaging (PET) as a diagnostic tool in prostate cancer – Dr. Tanya Dorff
8:25 AM to 8:50 AM PST: Systemic therapy in biochemical recurrence – Dr. Benjamin L. Maughan
8:50 AM to 9:00 AM PST: Discussion
9:00 AM to 9:30 AM PST: Break
9:30 AM to 9:55 AM PST: Updates in cellular and molecular testing to define prognosis and personalized therapy – Dr. Umang Swami
9:55 AM to 10:20 AM PST: Novel immune therapy approaches for metastatic prostate cancer: advances in systemic therapy – Dr. Ulka Vaishampayan
10:20 AM to 10:30 AM PST: Discussion
10:30 AM to 10:35 AM PST: Concluding remarks
This meeting is held virtually on Zoom. Register for the activity to participate.
Once you sign up, you will receive a confirmation email. However, you will not receive a zoom link via email to join this meeting.
You will need to log into the activity page to access the zoom link on the day of the meeting. The link will be accessible about 30 minutes before the meeting starts.
More faculty coming soon!
Benjamin Maughan, MD, PharmD
Assistant Professor of Medicine
Huntsman Cancer Institute, University of Utah
Ulka Vaishampayan, MD,
Professor of Medicine
University of Michigan
Umang Swami, MD
Assistant Professor of Medicine
Huntsman Cancer Institute, University of Utah
Tanya Dorff, MD
Associate Clinical Professor of Medicine
City of Hope
The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.
The Binaytara Foundation designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 2.0 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Nursing Contact Hours
Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.0 Contact Hours.
ABSM Maintenance of Certificate Recognition Statement:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 2.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 2.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.
Please support this meeting by visiting our sponsors and exhibitors in the main exhibit breakout room during the exhibit presentations.
Please note that exhibit presentations are promotional materials separate from the accredited activities. These presentations are held in the exhibit breakout room during designated exhibit hours.
We encourage you to visit the main exhibit breakout room and each company's breakout rooms during exhibit and break hours.
The following Exhibitors will be making exhibit presentations during the exhibit hours:
|Company||Reps Presenting||Link to Exhibit Materials and Prescribing information|
This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0.
If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid registration by industry participants will be invoiced an additional $150 for a total of $356.
You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity via Zoom, and completion of pre & post tests as well as course evaluations.
This activity is free for all healthcare providers who are not employees of an ineligible entity.
No refunds will be issued if you are unable to attend the live meeting after enrollment.
This activitywill be held virtually on Zoom. You will need access to internet and a hardware such as a laptop or desktop computer or a mobile device with Zoom application installed.
For best audio-visual experience, please update your Zoom application before joining the meeting.